Clinical Trial Update: HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for HEM-iSMART-C evaluating ruxolitinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine in pediatric patients with relapsed o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• CYTARABINE (CYTARABINE)
• DEXAMETHASONE (Dexamethasone)
• Ruxolitinib (ruxolitinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Princess Maxima Center for Pediatric Oncology | Conditions: Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1, Phase 2 | Status: RECRUITING